The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | VAG regimen drives immune reprogramming and superior remission in older/unfit patients with AML
In this interview, Hong-Hu Zhu, MD, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China, discusses the potential of the VAG regimen, a novel treatment approach for older or unfit patients with acute myeloid leukemia (AML) that combines venetoclax, azacitidine, and granulocyte colony-stimulating factor (G-CSF) and was evaluated in a Phase II trial (ChiCTR2300078290). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
